

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奥赛图(北京)医药科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

POLL RESULTS OF THE 2022 ANNUAL GENERAL MEETING HELD ON MAY 25, 2023

References are made to the notice (the “**Notice**”) and the circular (the “**Circular**”) of the AGM both dated May 3, 2023 of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Notice and the Circular.

The AGM was held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online on Thursday, May 25, 2023 at 10:00 a.m.. The AGM was held in accordance with the requirements of the PRC Company Law and the Articles.

As at the date of the AGM, the total number of issued shares of the Company was 399,398,420, including 110,781,920 H Shares and 288,616,500 Domestic and Unlisted Shares, all of which entitled the Shareholders to attend the AGM and vote for or against or abstain from voting on the resolutions (the “**Resolutions**”) proposed at the AGM. A total of 14 Shareholders and their proxies holding an aggregate of 366,487,580 voting Shares, representing approximately 91.76% of the total number of voting Shares, attended the AGM. Dr. Shen Yuelel, the chairman of the Company, acted as the chairman of the AGM and presided over it. All the Directors, the Supervisors, as well as the secretary of the Board were present at the meeting either in person or by means of telecommunication.

Pursuant to the Listing Rules and as advised by the Company's PRC legal advisors, Dr. Shen Yuelei and Dr. Ni Jian and their controlled corporations (Note 1), collectively holding 16,854,300 H Shares and 93,240,540 Domestic and Unlisted Shares, were required to, and had abstained from voting on the resolution numbered 10 at the AGM. In addition, (i) State Development & Investment Group Co., Ltd. ("SDIC") and its controlled corporations (Note 2), collectively holding 72,937,440 Domestic and Unlisted Shares; (ii) China Merchants Bank Co., Ltd. ("CMBC") and its controlled corporations (Note 3), collectively holding 26,088,480 H Shares and 51,171,840 Domestic and Unlisted Shares; (iii) China Life Chengda (Shanghai) Healthcare Equity Investment Management Company Limited, holding 14,296,320 Domestic and Unlisted Shares; (iv) Jiangsu China Life Jiequan Equity Investment Center (Limited Partnership), holding 9,222,840 Domestic and Unlisted Shares; (v) PICC Beijing Health Care Fund, L.P., holding 9,222,840 Domestic and Unlisted Shares; (vi) Shenzhen Zhaoyin Gongying Equity Investment Partnership (Limited Partnership), holding 1,355,760 Domestic and Unlisted Shares; (vii) Zhuhai Growth Win-Win Venture Capital Fund (Limited Partnership), holding 2,459,520 Domestic and Unlisted Shares; (viii) Beijing Yuanqing Bencao Equity Investment Center (Limited Partnership), holding 9,193,680 Domestic and Unlisted Shares and (ix) Suzhou Industrial Park Original Point Zhengze II Venture Capital Enterprise (Limited Partnership), holding 2,936,880 H Shares are investors of a related party contemplated under the resolution numbered 10, such parties had abstained from voting on the resolution numbered 10 at the AGM as advised by the Company's PRC legal advisors. Accordingly, the total Shares entitling the Shareholders to attend and vote on the resolution numbered 10 and other resolutions proposed at the AGM were 90,417,980 and 399,398,420 respectively. The total number of Shares with voting rights, on the resolution numbered 10 and other resolutions, represented by the Shareholders attending the AGM in person or by proxy was 57,507,140 and 366,487,580 representing approximately 63.60% and 91.76% of the total number of Share with voting rights, respectively.

Save as disclosed above, to the best of the Directors' knowledge, information and belief, no Shareholders were required to abstain from voting on any of the Resolutions in accordance with the requirements of the Listing Rules. There were no Shares entitling the holder(s) to attend the AGM but abstain from voting in favour of any of the Resolutions under rule 13.40 of the Listing Rules. None of the Shareholders had stated his/her/its intention to vote against or to abstain from voting on any of the Resolutions. The Company was not aware of any Shareholders indicating their intention to vote against any of the Resolutions or abstain from voting at the AGM. All Resolutions were put to vote by way of poll.

Note 1: Beijing Baiao Evergreen Technology Development Center (Limited Partnership)* (北京百奧常青科技發展中心(有限合夥)), Beijing Baiao Changsheng Technology Development Center (Limited Partnership)* (北京百奧常盛科技發展中心(有限合夥)), Beijing Eucure Evergreen Technology Development Center (Limited Partnership)* (北京祐和常青科技發展中心(有限合夥)) and Beijing Eucure Changsheng Technology Development Center (Limited Partnership)* (北京祐和常盛科技發展中心(有限合夥)).

Note 2: State Development & Investment Corporation (SDIC) VC Fund (Ningbo) of Technology Transfer and Commercialization (Limited Partnership), State Development & Investment Corporation (SDIC) VC Fund (Shanghai) of Technology Transfer and Commercialization (Limited Partnership) and State Development & Investment Corporation (SDIC) Gaoxin (Shenzhen) VC Fund (Limited Partnership).

Note 3: Astral Eminent Limited, Zhaoyin Chengzhang Qihao Investment (Shenzhen) Partnership (Limited Partnership) (招銀成長柒號投資(深圳)合夥企業(有限合夥)), Shenzhen Zhaoyin Langyao Growth Equity Investment Fund Partnership (L.P.) (深圳市招銀朗曜成長股權投資基金合夥企業(有限合夥)), Zhaoyin Chengzhang Shijiuhao Equity Investment Fund Partnership (Limited Partnership) (深圳市招銀成長拾玖號股權投資基金合夥企業(有限合夥)) and CMB International Capital Management (Shenzhen) Co., Ltd. (招銀國際資本管理(深圳)有限公司).

Tricor Investor Services Limited, the Company's H share registrar, two representatives from the Company's Shareholders and one Supervisor, were appointed as the scrutineer at the AGM for the purpose of vote-taking. The poll results in respect of the Resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		No. of Votes (%)		
		For	Against	Abstain
1.	To receive, consider and approve the annual report for 2022 and audited financial statements for 2022	366,487,580 (100.0000%)	0 (0.0000%)	0 (0.0000%)
2.	To receive, consider and approve the work report of the Board for 2022	366,487,580 (100.0000%)	0 (0.0000%)	0 (0.0000%)
3.	To receive, consider and approve the work report of the Supervisory Committee for 2022	366,487,580 (100.0000%)	0 (0.0000%)	0 (0.0000%)
4.	To receive, consider and approve the final accounts report for 2022	366,487,580 (100.0000%)	0 (0.0000%)	0 (0.0000%)
5.	To consider and approve the proposed re-appointment of KPMG, certified public accountants as the auditor of the Company for 2023 and authorize the Board to fix its remuneration	366,487,580 (100.0000%)	0 (0.0000%)	0 (0.0000%)
6.	To consider and approve the proposed remuneration of Directors for 2023	366,487,580 (100.0000%)	0 (0.0000%)	0 (0.0000%)
7.	To consider and approve the proposed remuneration of Supervisors for 2023	366,487,580 (100.0000%)	0 (0.0000%)	0 (0.0000%)
8.	To consider and approve the proposed 2022 profit distribution plan	366,487,580 (100.0000%)	0 (0.0000%)	0 (0.0000%)
9.	To review, consider and approve the proposed annual financial budget for 2023	366,459,580 (99.9924%)	28,000 (0.0076%)	0 (0.0000%)
10.	To consider and approve confirmation of Company's related party transactions from 2020 to 2022	57,507,140 (100.0000%)	0 (0.0000%)	0 (0.0000%)

As more than 50% of votes were casted in favour of each of the above ordinary Resolutions, all of the above Resolutions were duly passed at the AGM.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
*Chairman of the Board, Chief Executive Officer
and Executive Director*

Hong Kong, May 25, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.